

RESEARCH LETTER

Open Access



Desmocollin-1 is associated with pro-metastatic phenotype of luminal A breast cancer cells and is modulated by parthenolide

Petr Lapcik¹, Petr Sulc¹, Lucia Janacova¹, Katerina Jilkova¹, David Potesil², Pavla Bouchalova¹, Petr Müller³ and Pavel Bouchal^{1*} 

*Correspondence:
bouchal@chemi.muni.cz

¹ Department of Biochemistry, Faculty of Science, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
² Central European Institute of Technology, Masaryk University, Brno, Czech Republic
³ Masaryk Memorial Cancer Institute, RECAMO, Brno, Czech Republic

Abstract

Background: Desmocollin-1 (DSC1) is a desmosomal transmembrane glycoprotein that maintains cell-to-cell adhesion. DSC1 was previously associated with lymph node metastasis of luminal A breast tumors and was found to increase migration and invasion of MCF7 cells in vitro. Therefore, we focused on DSC1 role in cellular and molecular mechanisms in luminal A breast cancer and its possible therapeutic modulation.

Methods: Western blotting was used to select potential inhibitor decreasing DSC1 protein level in MCF7 cell line. Using atomic force microscopy we evaluated effect of DSC1 overexpression and modulation on cell morphology. The LC–MS/MS analysis of total proteome on Orbitrap Lumos and RNA-Seq analysis of total transcriptome on Illumina NextSeq 500 were performed to study the molecular mechanisms associated with DSC1. Pull-down analysis with LC–MS/MS detection was carried out to uncover DSC1 protein interactome in MCF7 cells.

Results: Analysis of DSC1 protein levels in response to selected inhibitors displays significant DSC1 downregulation (p -value ≤ 0.01) in MCF7 cells treated with NF- κ B inhibitor parthenolide. Analysis of mechanic cell properties in response to DSC1 overexpression and parthenolide treatment using atomic force microscopy reveals that DSC1 overexpression reduces height of MCF7 cells and conversely, parthenolide decreases cell stiffness of MCF7 cells overexpressing DSC1. The LC–MS/MS total proteome analysis in data-independent acquisition mode shows a strong connection between DSC1 overexpression and increased levels of proteins LACRT and IGFBP5, increased expression of IGFBP5 is confirmed by RNA-Seq. Pathway analysis of proteomics data uncovers enrichment of proliferative MCM_BIOCARTA pathway including CDK2 and MCM2-7 after DSC1 overexpression. Parthenolide decreases expression of LACRT, IGFBP5 and MCM_BIOCARTA pathway specifically in DSC1 overexpressing cells. Pull-down assay identifies DSC1 interactions with cadherin family proteins including DSG2,




CDH1, CDH3 and tyrosine kinase receptors HER2 and HER3; parthenolide modulates DSC1-HER3 interaction.

Conclusions: Our systems biology data indicate that DSC1 is connected to mechanisms of cell cycle regulation in luminal A breast cancer cells, and can be effectively modulated by parthenolide.

Keywords: DIA, Proteomics, Pull-down, DSC1, Breast cancer, Metastasis

Graphical Abstract



Introduction

Breast cancer represents the most prevalent and the most lethal cancer disease in the female population [1]. It is a heterogeneous disease that can be classified into intrinsic or molecular subtypes which differ in molecular profile, treatment strategy, response to treatment, and patient outcome [2]. These involve at least four molecular subtypes including luminal A, luminal B, HER2+ and triple negative [3, 4]. Generally, luminal A tumors that are the most prevalent and have the most favorable outcome express estrogen and progesterone receptors, do not express tyrosine-protein kinase erbB-2 (HER2/ERBB2) and show low levels of proliferation marker Ki-67 [5]. Although luminal B tumors also express hormonal receptors, these tumors can express HER2 and usually have higher proliferation potential associated with increased tumor aggressiveness [6]. On the other hand, HER2+ tumors lack hormonal receptors and overexpress HER2, whereas triple-negative tumors do not express any of these receptors. Both HER2+ and triple negative subtypes are associated with high grade and poor clinical prognosis [7]. For luminal A subtype, well established and effective treatment includes hormone therapy that targets estrogen and progesterone receptors and is based on tamoxifen or aromatase inhibitors [8, 9]. However, up to 16% of node-negative luminal A patients and up to a third of lymph node positive luminal A patients at the time of diagnosis develop distant metastasis [10, 11]. Moreover, about 20% to 30% of patients with estrogen receptor-positive tumors become resistant to the endocrine treatment [12]. Thus, development of more stratified approaches targeting the pro-metastatic mechanisms is of a high clinical need. For HER2+ subtype, trastuzumab treatment targeting HER2 receptor that is expressed on the surface of tumor cells, represents a prototype of a successful treatment that has reversed the prognosis of HER2+ patients to more favorable outcome.

In our previous study, we identified desmocollin-1 (DSC1) as a protein more abundant in more migrating population of MDA-MB-231 breast cancer cell line [13].

Subsequently, immunohistochemical analysis of 96 primary breast tumors revealed increased levels of DSC1 in lymph node positive luminal A tumors compared to their lymph node negative counterparts [13]. Increased levels of DSC1 were also observed in higher grade and HER2 + breast cancer subtypes and was associated with worse distant metastasis free survival in lymph node positive breast tumors [13]. Finally, DSC1 over-expression was associated with higher migration and invasiveness of MCF7 cells [13]. Generally, DSC1 is a transmembrane glycoprotein belonging to the cadherin family [14]. Cadherins participate in intercellular adhesion via desmosome formation and influence migration of cells [15], and potentially influence motility and invasion of tumor cells [16]. Based on these findings we hypothesize that DSC1 may play a role in metastasis of luminal A breast cancer and has a potential to serve as a therapeutic target. Here we aim at understanding the molecular role of DSC1 in breast cancer cells using proteomics [17] and RNA sequencing (RNA-Seq), analysis of its role in cell morphology, and at proposing the inhibitor that can modulate DSC1 protein levels and DSC1-related molecular mechanisms. Finally, we identify proteins interacting with DSC1 using pull-down assay and detect protein interactions targetable by DSC1 inhibition.

Materials and methods

Cultivation of cell lines

The MCF7 breast cancer cell line (ATCC, USA), stably transduced MCF7-DSC1-GFP line producing DSC1—Streptavidin-Binding Peptide—Green Fluorescent Protein (DSC1-SBP-GFP) fusion protein, and control MCF7-GFP line producing SBP-GFP fusion protein, both transduced lines prepared as described by Faktor et al. [13], were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Sigma-Aldrich, USA) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, USA) at 37 °C and 5% CO₂ to approximately 80% confluency. Cells were washed with sterile 0.5% EDTA in 1 × phosphate buffered saline (1 × PBS; 0.137 M NaCl; 2.68 mM KCl; 1.47 mM KH₂PO₄; 6.45 mM Na₂HPO₄) during passaging, harvested using 0.125% trypsin solution (Sigma-Aldrich, USA) and resuspended in DMEM with 10% FBS. The growth medium was periodically evaluated for mycoplasma contamination.

For the inhibitor selection, 250,000 MCF7 cells for each condition were placed on three 6 cm plates in 4.5 ml complete DMEM media supplemented with 10% FBS. Cells were subsequently cultivated for 24 h prior the transient transfection.

For the atomic force microscopy (AFM) experiment, the 3 cm plates were coated with 1 ml of sterile poly-L-lysine solution in water for one hour and then the solution was aspirated off. Stably transduced MCF7-DSC1-GFP and control MCF7-GFP cells were counted using Bürker's chamber and 80,000 cells were added to coated 3 cm plates. DMEM medium was filled to the total volume of 2 ml. Cells were further incubated with parthenolide at IC₅₀ concentration or dimethyl sulfoxide (DMSO) for 24 h.

For the total proteome experiment, MCF7-DSC1-GFP cells and control MCF7-GFP cells were grown on 6-well plates as above in three biological replicates per condition. 300,000 cells were placed on the wells. After 24 h, cells were treated with parthenolide at IC₅₀ concentration or DMSO and incubated for 24 h. Floating cells were stained using 0.4% trypan blue mixed 1:1 with cell suspension and counted using LUNA-II cell counter (Logos Biosystems, Inc.).

For the pull-down experiment, cell line MCF7-DSC1-GFP and control cell line MCF7-GFP were grown in three biological replicates, each replicate on three 15 cm plates to 70% confluency. Cells were further incubated with parthenolide at IC₅₀ concentration or DMSO for 24 h.

For the RNA-Seq experiment, MCF7-DSC1-GFP and MCF7-GFP cells were cultured on 6 cm plates and were incubated with parthenolide at IC₅₀ concentration or DMSO for 24 h. Cells were prepared in biological duplicates for each condition.

Transient transfection of MCF7 cells

MCF7 cells were transiently transfected using pLenti6.3-rbs-DSC1-GWs-C-HA-IRES-GFP plasmid. Transfection solution was prepared in the volume of 500 µl/6 cm plate. The solution consisted of 4 µg plasmid DNA and 12 µl polyethylenimide, ratio 1:3 dissolved in DMEM medium without FBS in final volume of 500 µl. Solution was incubated for 15 min at RT. The solution was administered on plates with cells in the next step and incubated for 12 h at 37 °C and at 5% CO₂. After 12 h DMEM medium was replaced with fresh DMEM. Transfection efficacy was checked using fluorescent microscopy.

Selection of DSC1 inhibitor

Transiently transfected MCF7 cells were treated with inhibitors niclosamide (chemical purity 99.4%, Sigma-Aldrich), norcantharidine (chemical purity 99.5%, Sigma-Aldrich) and parthenolide (chemical purity 98%, Sigma-Aldrich) that were selected based on our previous study [11]. Each inhibitor was added to reach its IC₅₀ concentration – 1.68 µM for niclosamide, 270.6 µM for norcantharidin and 12.8 µM for parthenolide. Control cells were treated with DMSO (Sigma-Aldrich). Cells were incubated for 24 h at 37 °C and 5% CO₂. After incubation, significant number of cells lost its adherent state, hence growth media were centrifugated at 1000 × g for 5 min at RT. Adherent cells were washed 2 times with 1.5 ml 1 × PBS. Adherent and pelleted cells were harvested, pooled, and lysed in a buffer containing 250 mM Tris/HCl pH 6.8, 10% SDS, 30% glycerol, 5% β-mercaptoethanol and 0.02% bromophenol blue at 95 °C. Cell lysate was subsequently incubated at 95 °C for 10 min. Protein concentrations were determined using RC-DC protein assay kit (Bio-Rad, USA) according to manufacturer's instructions.

Western blot analysis

30 µg of a total protein was loaded on 10% separation and 5% concentration sodium dodecyl sulfate–polyacrylamide gel and electrophoretically separated as previously described [18]. Separated proteins were transferred onto a nitrocellulose blotting membrane BioTrace™ NT, pure Nitrocellulose, 0.22 µm (Pall Life Sciences, Mexico) in a blotting buffer (20% methanol, 0.19 M glycine, 24.8 mM Tris Base) at 100 V for 75 min. The efficiency of blotting was tested using Ponceau S solution (2.63 mM Ponceau S, 0.14 M sulfosalicylic acid, 0.18 M trichloroacetic acid). Membranes were blocked for 1 h in a 5% non-fat dried milk in 0.1% Tween+1 × PBS. Next, rabbit polyclonal anti-DSC1 antibody (ab198904, Abcam, UK, dilution 1:1000) was used to detect DSC1. Primary antibody was diluted in a 5% non-fat dried milk in 0.1% Tween-20+1 × PBS. Mouse monoclonal anti-actin antibody clone AC-40 (A4700, Sigma-Aldrich, USA, dilution 1:1000) was used as a loading control. For detection of fusion proteins with SBP tag,

anti-SBP antibody was used (MAB10764, Merck, USA, dilution 1:2000). Membranes were incubated overnight with primary antibodies at 4 °C and subsequently washed in 1 × PBS and 0.1% Tween + 1 × PBS both twice. Corresponding secondary antibodies conjugated with horseradish peroxidase were diluted in 5% non-fat dried milk in 0.1% Tween-20 + 1 × PBS to 1:1000 and incubated with membranes for 60 min at RT. Membranes were then washed again in PBS and 0.1% Tween + 1 × PBS both twice and incubated with freshly prepared enhanced chemiluminescence (ECL) solution composed from solution A (10 mM luminol, 0.5 mM EDTA, 405 μM coumaric acid, 200 mM Tris pH 9.4) and solution B (0.5 mM EDTA, 8 mM sodium perborate tetrahydrate, 50 mM sodium acetate pH 5) mixed in 1:1 ratio. ECL solution was removed after 5 min incubation and chemiluminescence was detected on a Fusion Fx Spectra (Vilber Lourmat, France). Semiquantitative analysis of the signals was performed using QuantityOne 4.6 software (Bio-Rad, USA) with signal comparison of DSC1 to actin in Microsoft Excel using Student *t*-test, results were visualized in GraphPad Prism 8.4.3. As the best performing inhibitor, parthenolide was selected for the following experiments.

Atomic force microscopy

After the growth medium replacement, cells were analyzed with AFM microscope Nano Wizard 3 (JPK Instruments, Germany) using AFM probe HYDRA-ALL (force mapping, contact mode, set point 100 nm; AppNano, USA) with tip in shape of tetrahedral pyramid. Data were evaluated in JPK Data Processing 5 software and Gwyddion 2.46 and afterwards illustrated by boxplots in GraphPad Prism 8.4.3 comparing the cell stiffness and cell height of the stably transduced MCF7-DSC1-GFP and MCF7-GFP treated with either parthenolide or DMSO. Statistical significance of the differences between these two cell lines in cell stiffness and cell height was calculated in GraphPad Prism 8.4.3 using a two-tailed Student *t*-test for normal data layout ($p=0.05$).

Sample preparation for total proteome analysis

During cell harvesting, DMEM media containing floating cells was removed and wells were washed twice with 1 × PBS, which was then added to the removed media and centrifuged at 1000 × *g*, 4 °C for 5 min. Supernatant was removed and pellet was resuspended in 1 × PBS. 1 × PBS was added to adherent cells in wells, which were scraped and pooled with cells from media. Cells were centrifuged at 1000 × *g*, 4 °C for 5 min. Lysis buffer (6 M guanidine hydrochloride, 0.1 M Na-phosphate, pH 6.6, 1% Triton X-100) was added to the wells to lyse the rest of unscraped cells to maintain the highest yield. This “conditioned” lysis buffer was used to lyse the pellets containing originally floating cells and cells scraped in 1 × PBS. Finally, samples were subsequently sonicated using HD 2200 (Bandelin, Germany) 30 × 0.1 s with power 50 W and after 30 s pause again 30 × 0.1 s with power 50 W. Cells were kept on ice during the sonication. Next, samples were incubated for 75 min at RT and centrifuged for 20 min at 4 °C and 14,000 × *g*. After centrifugation, supernatant was collected. Protein concentration was determined using RC-DC Protein Assay kit (Bio-Rad, USA).

Pull-down assay

Growth medium was removed, cells were placed on ice and washed with ice cold 1 × PBS three times. Cells were then washed with 2 × concentrated Complete™, EDTA-free Protease Inhibitor Cocktail (Roche, Switzerland) in 1 × PBS. Another 2 × protease inhibitor cocktail was added, cells were scraped and centrifuged for 5 min at 1000 × g, 4 °C. Supernatant was removed and pelleted cells were stored at – 80 °C. Cell pellets placed on ice were resuspended in 1 ml HNN-lysis buffer (0.5% NP40, 0.2 M Na₃VO₄, 1 mM PMSE, 1 × Complete™, EDTA-free Protease Inhibitor Cocktail (Roche, Switzerland), 1.2 μM avidine). Cell suspension was incubated for 10 min on ice and centrifuged for 20 min at 13,000 × g, 4 °C. During centrifugation, Micro BioSpin® 6 Columns (BioRad, USA) were equilibrated using 250 μl HNN-lysis buffer. 100 μl High Capacity Streptavidin Agarose Resin (Thermo Fisher Scientific, USA) was resuspended in 750 μl HNN-lysis buffer. Supernatants from samples were mixed with 200 μl streptavidin beads per sample. Samples were incubated on a rotation wheel for 15 min at 4 °C. Samples were subsequently transferred on equilibrated columns and washed twice with 1 ml HNN-lysis buffer and three-times with 1 ml HNN-buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 50 mM NaF) without protease inhibitors and detergents. All washing steps were performed using gravity flow. Samples were finally eluted using 200 μl 2.5 mM biotin solution in HNN-buffer without protease inhibitors and detergents. Elution step was performed three times.

Protein digestion and peptide desalting

Protein samples for total proteome and pull-down analysis were submitted to trypsin digestion using Filter-Aided Sample Preparation (FASP) method [19] and desalted as previously described [20]. Briefly, 100 μg of protein per total proteome sample or the whole pull-down eluates were transferred to the Microcon filter device, cut-off 30 kDa (Millipore, Germany) with 8 M urea in 0.1 M Tris/HCl, pH 8.5, reduced by tris(2-carboxyethyl)phosphine), alkylated using iodoacetamide, digested overnight by trypsin (Promega, USA) in the ratio 1:30, and resulting peptides were desalted on MicroSpin columns C18 (Nest Group, USA). Desalted peptides were dried in SpeedVac concentrator and stored at – 20 °C.

LC–MS/MS measurement

The dried peptides were solubilized using 50 μl of 2.5% formic acid (FA) in 50% acetonitrile (ACN), then 100 μl of pure ACN was added and the samples were concentrated using SpeedVac concentrator (Thermo Fisher Scientific) to 20 μl. Finally, the concentrated samples were diluted into LC–MS vials to get peptide concentration of 0.8 μg/μl with addition of 1 μl 0.01% of polyethylene glycol (BioUltra, 20,000, Sigma-Aldrich) [21] in water, 1 μl of stock iRT peptides standard (Biognosys), 2 μl of 5% FA and filled into 10 μl by MilliQ water (Merck). Two μg of peptides mixture was injected for each sample.

Liquid chromatography-tandem mass spectrometry (LC–MS/MS) analyses were done using RSLCnano system online connected to Orbitrap Fusion™ Lumos™ tribrid mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Prior to LC separation, tryptic digests were online concentrated and desalted using trapping column (100 μm × 30 mm) filled with 3.5-μm X-Bridge BEH 130 C18 sorbent (Waters, Milford,

MA, USA). After washing of trapping column with 0.1% FA, the peptides were eluted from the trapping column onto analytical Acclaim Pepmap100 C18 column (3 μm particles, 75 μm \times 500 mm; Thermo Fisher Scientific, Waltham, MA, USA) by the following gradient program (mobile phase A: 0.1% FA in water; mobile phase B: 0.1% FA in 80% ACN; flow 300 nl/min): the gradient elution started at 5% of mobile phase B and began increase in the 5th min to 37% during the 109 min, then reached to 80% of mobile phase B in the next 6 min and remained at this state for the last 10 min. Equilibration of the trapping column and the analytical column was done prior to sample injection to sample loop. The analytical column outlet was directly connected to the Digital PicoView 550 (New Objective) ion source. Active Background Ion Reduction Device (ESI Source Solutions) was installed. MS data were acquired in a data-independent acquisition (DIA) mode.

Orbitrap analyzer and quadrupole mass filter were employed for survey scan detection (350–1650 m/z). The MS scan resolution was 120,000 (at 200 m/z) with a target value of 2×10^5 ions and maximum injection time of 100 ms. After the MS scan, defined m/z segments were isolated by quadrupole mass filter and higher-energy collisional dissociation (HCD) fragmentation was done with a target value of 5×10^5 ions. MS/MS spectra after HCD fragmentation (default charge state is 2 and 28% collision energy) were recorded in Orbitrap with a resolution of 30,000 (at 200 m/z) in scan range of 200–1800 m/z . The maximum injection time for MS/MS was 50 ms.

Mass spectrometry data processing

DIA data were analyzed in Spectronaut software (Biognosys) version 13.6 for total proteome experiment and 13.9 for pull-down experiment, both in directDIA mode. UniProt/SwissProt database version 2019_07 downloaded on 2019-09-16 limited to human entries containing 20,431 sequences was used for database searches. Carbamidomethylation (C) was used as fixed modification, oxidation (M) and acetylation (protein N-term) were used as variable modifications. q -value at both precursor and protein levels were set to 0.01. For the total proteome experiment, data based on q -value 0.25 percentile (identified in 3 of 12 total runs) were involved in the final dataset. For the pull-down analysis, data based on q -value 0.33 percentile (identified in 3 of 9 total runs) were involved in the final dataset. Analysis of differential protein abundance was performed using t -test implemented in Spectronaut with false discovery rate correction. Default settings were used for other parameters.

Sample preparation for transcriptomics analysis

The cells were washed two times with cold $1 \times$ PBS on ice. The cells were harvested by adding 500 μl of $1 \times$ PBS and scraping by a cell scraper, transferred to an Eppendorf tube, and stored on ice. After centrifuging ($1000 \times g$, 4 $^{\circ}\text{C}$, 5 min), the supernatant was aspirated and 360 μl of TRI reagent was added to the pelleted cells. Total RNA was isolated according to TRI reagent protocol (T9424, Sigma-Aldrich) and its concentration was determined using Qubit RNA BR assay kit (Q10210, Thermo Fisher Scientific) and RNA integrity and quality (cut-off > 8.0) using Qubit RNA IQ Assay Kit (Q33221, Thermo Fisher Scientific). 240 ng of total RNA at 20 ng/ μl was used in RNA-Seq analysis. Samples were stored at -80 $^{\circ}\text{C}$.

RNA-Seq analysis

The TruSeq Stranded Total RNA LT Sample Prep Kit (Illumina) was used to convert 0.5 mg of total RNA into a library of template molecules. Library was validated using Bioanalyzer (DNA 1000 Kit, Agilent) and quantified according to manufacturer instructions by qPCR (KAPA Library Quantification Kit Illumina platforms, Kapa Biosystems) using Quant studio (QuantStudio 5, Thermo Fisher Scientific). Samples were sequenced using NextSeq 500 (Illumina).

RNA-Seq data processing

For RNA-seq, the raw reads were filtered to remove the adaptors and low-quality bases using Trimmomatic (v0.36) with Truseq2 as well as any reads that were shorter than 65 bases. Filtered reads were aligned to the human genome (Homo_sapiens.GRCh38.dna.primary_assembly) using STAR (v2.5.2b) in end-to-end mode to scan splice junctions. Then the counts in exon genomic features were calculated subread (v1.5.2). Differential expression analysis was performed in R 3.5.3 under the Deseq2 package version 1.22.2.

Gene set enrichment analysis

Gene set enrichment analysis (GSEA) in GSEA Java desktop application [22] version 4.3.2 was conducted using the list of all quantified proteins from total proteome analysis pre-ranked according to the negative log₂ of the *q*-value and the sign of the log₂ FC to identify enriched pathways, with a priori defined pathways from BioCarta database. Minimal size of a gene set was adjusted to 10, otherwise default settings were used.

GSEA analysis of pull-down data was performed with minimal gene set size set to 2 and with use of Gene Ontology Biological Process (GOBP) database. False positive and false negative interacting partners (i) with log₂ FC > 0 in pull-down and simultaneously log₂ FC > 0 and *q*-value < 0.05 in total proteome analysis, or (ii) with log₂ FC < 0 in pull-down and simultaneously log₂ FC < 0 and *q*-value < 0.05 in total proteome analysis, were excluded from the pull-down GSEA analysis.

GSEA analysis of the RNA-Seq data was performed with the same settings as in the total proteome experiment for all quantified protein-coding transcripts with use of the BioCarta database.

Results

NF-κB inhibitor parthenolide modulates DSC1 expression

In the present study, we tested nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitor parthenolide, cyclin-dependent kinase 2 (Cdk2) inhibitor norcantharidin and NF-κB inhibitor niclosamide to identify inhibitor decreasing protein levels of DSC1. Inhibitor experiments were performed in MCF7 cell line transiently transfected with a vector carrying *DSC1* gene and control cells. Significant decrease of both longer (Fig. 1A, *p*-value < 0.01) and shorter isoform (Fig. 1B, *p*-value < 0.01) of DSC1 protein were found in cells treated with parthenolide compared to the control, other inhibitors did not exhibit any effect (Fig. 1A, B, Additional file 1: Fig. S1 and Table S1). These results suggest that parthenolide has a significant downregulating effect on DSC1 protein levels and that DSC1 is sensitive to potential anti-metastatic inhibitors in luminal breast cancer cells.




Fig. 1 Statistical evaluation of semiquantitative analysis of inhibitor effects on DSC1 **A** preprotein **B** active protein levels. AFM was used to measure stiffness and height of MCF7-DSC1-GFP and control MCF7-GFP cell line (**C**). Comparison of **D** height and **E** stiffness of cells MCF7-DSC1-GFP and MCF7-GFP treated with parthenolide (PTL) and control cells. ***p*-value < 0.01, *****p*-value < 0.0001

Parthenolide decreases stiffness of MCF7 cells specifically overexpressing DSC1

Based on the above findings, we investigated whether parthenolide is effective in functional experiments on both cellular and molecular level. Cell stiffness and height of the stably transduced MCF7-DSC1-GFP cell line were compared to MCF7-GFP cells using AFM (Fig. 1C). Both cell lines were treated with either parthenolide or DMSO as a control. Height of MCF7-DSC1-GFP cells was significantly (p -value = $5.66E-3$) lower compared to MCF7-GFP cells (Fig. 1D). Parthenolide specifically and significantly (p -value = $6.71E-6$) decreased stiffness of cells overexpressing DSC1 (Fig. 1E). These results indicate that DSC1 overexpression and parthenolide treatment affect MCF7 cell line morphology.

DSC1 overexpression is associated with upregulation of proliferative pathways in MCF7 cells that are targetable by parthenolide

To characterize molecular mechanisms associated with DSC1 overexpression and parthenolide-induced DSC1 inhibition in MCF7 cell line, total proteome and transcriptome changes in MCF7-DSC1-GFP cells overexpressing DSC1 and control MCF7-GFP cells with parthenolide or DMSO treatment were evaluated. The adherent cells were harvested together with the floating cells which represent mixture of living and dead cells with $28.01 \pm 4.26\%$ and $37.99 \pm 4.12\%$ viability in MCF7-DSC1-GFP and MCF7-GFP cells treated with parthenolide, respectively, illustrating the activity of the inhibitor. Proteins from the cell lysates were identified and quantified using LC-MS/MS analysis in DIA mode and transcripts were identified and quantified using RNA-Seq approach.

3505 protein groups (FDR < 0.01, Additional file 2, for representative iRT peptide chromatograms please see Additional file 1: Fig. S2) and 17,157 protein-coding transcripts (Additional file 3) were quantified. DSC1 overexpression confirmed by increased DSC1 protein (q -value = $5.53E-49$, \log_2 FC = 4.07) and transcript (q -value = $6.2E-129$, \log_2 FC = 14.02) levels led to statistically significant (q -value < 0.05) up-regulation (protein \log_2 FC > 0.58, transcript \log_2 FC > 1) and down-regulation (protein \log_2 FC < - 0.58, transcript \log_2 FC < - 1) of 151 and 129 proteins, respectively (Additional file 2), and 276 and 268 transcripts, respectively (Additional file 3) (MCF7-DSC1-GFP vs. MCF7-GFP comparison). The most up-regulated proteins include extracellular glycoprotein lacritin (LACRT) and insulin-like growth factor-binding protein 5 (IGFBP5) that plays a role in cell proliferation, apoptosis, and survival (Additional file 1: Table S2). Increased protein levels were observed also for groups of proteins involved in cell proliferation (USP8, KIF23, RACGAP1, NUMA1, STMN1 and IQGA3) and cell adhesion (FREM2, TMOD3, NRCAM, BCAM) (Additional file 1: Table S2). Total of 14 genes displayed increased expression on both protein and transcript level in DSC1 overexpressing cells (Table 1) with IGFBP5 as the most stimulated gene at the protein level.

On the other hand, parthenolide treatment of DSC1 overexpressing cells (MCF7-DSC1-GFP + PTL vs. MCF7-DSC1-GFP comparison) was associated with significant down-regulation of 274 proteins and 655 transcripts. On the protein level, the most deregulated were LACRT and IGFBP5 (Additional file 1: Table S2). From the genes with increased expression both on protein and transcript level after DSC1 overexpression, only IGFBP5 displayed decreased protein and transcript levels in DSC1 overexpressing cells treated with parthenolide (Table 1), however DSC1 protein downregulation

Table 1 Genes upregulated after DSC1 overexpression both on protein (q -value < 0.05, \log_2 FC > 0.58) and mRNA level (q -value < 0.05, \log_2 FC > 1)

Gene name	UniProt ID	Protein description	MCF7-DSC1-GFP vs. MCF7-GFP		MCF7-DSC1-GFP + PTL vs. MCF7-DSC1-GFP		MCF7-GFP + PTL vs. MCF7-GFP		MCF7-DSC1-GFP + PTL vs. MCF7-GFP + PTL							
			Proteomics	Transcriptomics	Proteomics	Transcriptomics	Proteomics	Transcriptomics	Proteomics	Transcriptomics						
			\log_2 FC	q -value	\log_2 FC	q -value	\log_2 FC	q -value	\log_2 FC	q -value						
DSC1	Q08554	Desmocollin-1	4.07	4.98E-49	14.02	6.21E-129	-0.52	3.31E-28	0.06	0.869	-1.38	0.344	4.74	2.07E-40	15.45	1.53E-70
IGFBP5	P24593	Insulin-like growth factor-binding protein 5	2.87	2.92E-04	1.84	2.76E-40	-2.50	0.014	-1.03	8.17E-13	-2.27	1.63E-60	1.39	0.089	3.08	4.08E-111
MYO5C	Q9NQX4	Unconventional myosin-Vc	2.59	1.10E-03	2.14	2.76E-68	-0.36	0.010	0.12	0.546	0.02	0.938	2.81	3.40E-03	2.23	2.34E-74
SPPL2A	Q8TCT8	Signal peptide peptidase-like 2A	2.55	3.83E-04	2.08	3.40E-67	-0.21	0.141	0.33	0.021	0.27	0.076	2.81	1.83E-03	2.14	6.81E-71
SLC27A2	O14975	Very long-chain acyl-CoA synthetase	2.37	1.17E-08	1.74	3.52E-14	-0.55	7.61E-05	-0.22	0.501	-0.88	1.36E-03	2.70	2.03E-07	2.75	7.14E-32
USP8	P40818	Ubiquitin carboxyl-terminal hydrolase 8	2.21	7.99E-07	1.88	6.02E-48	0.24	5.70E-05	0.46	1.45E-03	0.38	0.014	2.00	3.92E-11	1.97	2.86E-53
FREM2	Q55ZK8	FRA51-related extracellular matrix protein 2	1.44	2.20E-14	1.12	1.07E-22	2.28	1.14E-06	-1.44	7.03E-38	-1.67	9.36E-51	0.14	0.131	1.35	1.61E-32

Table 1 (continued)

Gene name	UniProt ID	Protein description	MCF7-DSC1-GFP vs. MCF7-GFP		MCF7-DSC1-GFP + PTL vs. MCF7-DSC1-GFP		MCF7-GFP + PTL vs. MCF7-GFP		MCF7-DSC1-GFP + PTL vs. MCF7-GFP + PTL									
			log ₂ FC	q-value	log ₂ FC	q-value	log ₂ FC	q-value	log ₂ FC	q-value	log ₂ FC	q-value						
RHOB	P62745	Rho-related GTP-binding protein RhoB	1.24	1.17E-07	1.06	7.28E-10	-0.55	1.26E-06	-0.11	0.695	0.12	0.162	0.46	0.013	0.57	2.52E-04	0.48	0.017
TMOD3	Q9NYL9	Tropomodulin-3	1.06	8.46E-16	1.70	1.90E-45	0.16	1.42E-03	0.23	0.131	0.29	2.09E-04	0.00	0.992	0.93	2.21E-14	1.93	1.40E-58
TOM1L1	O75674	TOM1-like protein 1	1.03	1.01E-06	1.18	1.16E-21	0.11	7.91E-03	-0.07	0.728	0.18	0.039	-0.17	0.302	0.95	1.38E-04	1.28	3.87E-25
FKBP10	Q96AY3	Peptidyl-prolyl cis-trans isomerase FKBP10	0.95	0.013	1.24	7.16E-14	-0.46	0.021	-0.73	2.97E-05	-0.67	5.26E-04	-1.44	7.32E-17	1.17	0.017	1.95	1.65E-30
CKMT1A	P12532	Creatine kinase U-type, mitochondrial	0.94	7.41E-07	1.32	1.47E-06	-0.41	2.53E-03	-0.29	0.412	-0.67	1.37E-06	0.01	0.984	1.20	8.28E-09	1.01	4.75E-04
LXN	Q9BS40	Latexin	0.86	2.51E-12	2.57	1.01E-65	-0.33	1.39E-03	1.18	1.60E-14	0.20	0.020	1.21	7.20E-15	0.34	8.17E-06	2.53	6.06E-66
MYO5A	Q9Y411	Unconventional myosin-Va	0.85	7.98E-05	1.72	5.19E-33	-0.06	0.125	0.75	6.53E-07	-0.38	0.023	0.49	2.30E-03	1.18	2.42E-04	1.98	2.39E-44
LMCD1	Q9NZU5	LIM and cysteine-rich domains protein 1	0.83	1.40E-03	1.45	1.44E-13	0.26	8.84E-03	1.54	6.55E-18	0.59	1.57E-03	1.59	5.95E-17	0.51	0.011	1.39	1.57E-14

PTL parthenolide

by parthenolide was observed also in control cells (MCF7-GFP + PTL vs. MCF7-GFP comparison). Parthenolide alters DSC1-induced up-regulation of LACRT and IGFBP5 proteins in MCF7-DSC1-GFP cells compared to control MCF7-GFP cells, both treated with parthenolide (MCF7-DSC1-GFP + PTL vs. MCF7-GFP + PTL comparison). These results suggest LACRT and IGFBP5 as the most co-expressed genes with DSC1 in breast cancer cells that can be modulated with parthenolide treatment.

GSEA analysis was performed to define biological pathways associated with DSC1 overexpression and parthenolide-induced DSC1 inhibition on protein and transcript levels. DSC1 overexpression in MCF7 cells was associated with statistically significant (FDR q -value < 0.05) positive enrichment of 2 protein BIOCARTA pathways (Fig. 2), namely MCM and VDR pathways, from which MCM pathway consists of Cdk2 and helicases minichromosome maintenance (MCM) 2–7, and VDR pathway contains proteins involved in chromatin remodeling (Additional file 4). Parthenolide treatment of DSC1 overexpressing cells resulted in negative enrichment of 4 pathways, including MCM pathway. However, the parthenolide-induced negative enrichment of MCM pathway was specific for DSC1 overexpressing cells as the parthenolide did not induce negative enrichment of MCM pathway in the control cell line (Fig. 2). The negative enrichment of MCM pathway after parthenolide treatment specifically in DSC1 overexpressing cell line was observed also on the transcriptome level, although with lesser statistical significance (FDR q -value = 0.061) (Fig. 2, Additional file 4). These results indicate DSC1 overexpression in MCF7 cells to be associated with increased expression of genes involved in DNA replication and cell cycle progression.

BIOCARTA PATHWAY NAME	PROTEIN				mRNA			
	MCF7-DSC1-GFP vs. MCF7-GFP	MCF7-DSC1-GFP+ PTL vs. MCF7-DSC1-GFP	MCF7-GFP+ PTL vs. MCF7-GFP	MCF7-DSC1-GFP+ PTL vs. MCF7-GFP+ PTL	MCF7-DSC1-GFP vs. MCF7-GFP	MCF7-DSC1-GFP+ PTL vs. MCF7-DSC1-GFP	MCF7-GFP+ PTL vs. MCF7-GFP	MCF7-DSC1-GFP+ PTL vs. MCF7-GFP+ PTL
MCM	●	●				○		
VDR	●		○	○				
EIF		○	○					
PPARA		○	○					
HIVNEF		●	●					
TNFR1		●	●					
FAS		●	●					
INTEGRIN			○					
MTOR			○					
EIF4				○				




Fig. 2 Gene set enrichment analysis of proteomics and transcriptomics profile comparisons of MCF7-DSC1-GFP and MCF7-GFP cells treated and untreated with parthenolide. PTL parthenolide

In conclusion, DSC1 overexpression in MCF7 cells is related to increased expression of LACRT and IGFBP5 gene and proliferative MCM pathway. Parthenolide decreased LACRT and IGFBP5 protein and IGFBP5 transcript levels and suppressed MCM pathway specifically in DSC1 overexpressing MCF7 cells.

Parthenolide modulates interactions of DSC1 with cell adhesion molecules and HER3

We performed a pull-down experiment to identify new potential DSC1 interacting partners binding to its N-terminus, as the DSC1-SBP-GFP fusion protein produced in MCF7-DSC1-GFP cells contains SBP tag attached to the C-terminus of DSC1, and to evaluate the ability of parthenolide to modulate these interactions. Presence of SBP tag in MCF7-DSC1-GFP cell line and control MCF7-GFP line was confirmed using western blot with immunodetection (Additional file 1: Fig. S3). Analysis of interacting partners in vitro was performed using pull-down assay with subsequent identification by LC-MS/MS in DIA mode. Total of 706 proteins were identified (Additional file 5). From these, 250 proteins are potential interacting partners of DSC1 (q -value < 0.05 and \log_2 FC > 1 in pull-down comparison MCF7-DSC1-GFP vs. MCF7-GFP), from which 54 were significantly downregulated by parthenolide (q -value < 0.05 and \log_2 FC < -1 in pull-down comparison MCF7-DSC1-GFP + PTL vs. MCF7-DSC1-GFP). Pull-down results were compared with results of total proteome analysis to prevent from false positive interactions that could be caused by increased protein abundance in pull-down due to gene co-expression with DSC1. Out of 250 potential interacting partners, 184 proteins (Additional file 5) were not found co-expressed with DSC1 in total proteome analysis (\log_2 FC < 0 or \log_2 FC > 0 and q -value > 0.05 or not identified in MCF7-DSC1-GFP vs. MCF7-GFP comparison in total proteome analysis). 23 of these not co-expressed potential interactors (Tab. 2, Fig. 3A) were modulated by parthenolide (q -value < 0.05 and \log_2 FC < 1 in pull-down comparison MCF7-DSC1-GFP + PTL vs. MCF7-DSC1-GFP). These proteins include desmoglein 2 (DSG2) that is essential for desmosome formation and is a known interactor of DSC1, which validates the results of this experiment. Moreover, cadherins 1 (CDH1) and cadherin 3 (CDH3), four protocadherins and cadherin receptor CELR2 that play role in cell adhesion were shown to interact with DSC1 as well. Parthenolide also inhibits interaction of DSC1 with receptor tyrosine-protein kinase erbB-3 (HER3/ERBB3) that is involved in cell proliferation.

GSEA of the pull-down identified proteins (Fig. 4) highlights participation of DSC1 potentially interacting proteins in 4 enriched (FDR q -value < 0.10) Gene ontology biological process (GOBP) pathways that play a role in cell adhesion (Additional file 6). These pathways involved desmosomal proteins including DSG2, catenin alpha-1 (CTNA1), CDH1 and CDH3, and HER2 that is linked to proliferation regulation. The ability of parthenolide to alter protein-protein interactions of DSC1 with desmosomal proteins was demonstrated by negative enrichment of three GOBP pathways (Fig. 4).

Analysis of known interacting partners of DSC1 was performed in the STRING database. The interaction site of DSC1 (Fig. 3B) showed mainly interactions of DSC1 with proteins forming the desmosome structures (DSG2) and with proteins envoplakin (EVPL) and periplakin (PPL) that represent components of keratinocytes that contain

Table 2 23 potential interacting partners of DSC1 identified using pull-down assay that can be modulated with parthenolide

Protein name	Protein description	UniProt ID	Gene name	Pull-down MCF7-DSC1-GFP vs. MCF7-GFP		Pull-down MCF7-DSC1-GFP vs. DSC1-GFP		Total proteome MCF7-DSC1-GFP vs. MCF7-GFP		Total proteome MCF7-DSC1-GFP + PTL vs. MCF7-DSC1-GFP	
				log ₂ FC	q-value	log ₂ FC	q-value	log ₂ FC	q-value	log ₂ FC	q-value
DSG2	Desmoglein-2	Q14126	DSG2	7.21	6.82E-53	-2.01	1.70E-52	-0.45	0.106	0.01	2.64E-04
CELR2	Cadherin EGF LAG seven-pass G-type receptor 2	Q9HCU4	CELSR2	5.88	7.04E-53	-2.03	1.29E-45	NA	NA	NA	NA
PCDGD	Protocadherin gamma-B1	Q9Y5G3	PCDHGB1	5.22	8.02E-06	-1.32	1.60E-05	NA	NA	NA	NA
ALG11	GDP-Mann(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase	Q2TAA5	ALG11	5.15	4.75E-10	-2.24	2.35E-10	NA	NA	NA	NA
CADH1	Cadherin-1	P12830	CDH1	5.11	1.20E-14	-1.39	1.28E-13	-0.02	1.79E-03	-0.09	0.224
CDIPT	CDP-diacylglycerol-inositol 3-phosphatidyltransferase	O14735	CDIPT	5.11	2.56E-09	-2.30	1.45E-06	-0.35	2.00E-03	-0.01	0.122
SATT	Neutral amino acid transporter A	P43007	SLC1A4	3.86	5.27E-04	-2.41	4.09E-03	NA	NA	NA	NA
PCDGH	Protocadherin gamma-B5	Q9Y5G0	PCDHGB5	3.77	6.88E-04	-1.10	5.46E-04	NA	NA	NA	NA
PCDBD	Protocadherin beta-13	Q9Y5F0	PCDHBT3	3.70	1.82E-06	-2.29	1.71E-03	NA	NA	NA	NA
TM165	Transmembrane protein 165	Q9HC07	TMEM165	3.68	3.12E-03	-1.33	4.51E-03	-0.41	9.12E-06	-0.08	0.234
TIM23	Mitochondrial import inner membrane translocase subunit Tim23	O14925	TIMM23	3.50	1.02E-03	-1.25	0.032	0.10	0.131	-0.03	0.244
UPK3L	Uropod-like protein 1	B0FP48	UPK3BL1	3.39	1.13E-10	-1.08	5.46E-04	NA	NA	NA	NA
TNPO1	Transportin-1	Q92973	TNPO1	3.18	8.96E-06	-1.16	4.33E-03	0.02	0.139	0.17	9.29E-03
FAT1	Protocadherin Fat 1	Q14517	FAT1	2.96	1.58E-14	-1.98	4.15E-12	NA	NA	NA	NA
CADH3	Cadherin-3	P22223	CDH3	2.89	5.37E-06	-2.21	2.58E-03	NA	NA	NA	NA
SFXN4	Sideroflexin-4	Q6P4A7	SFXN4	2.78	2.14E-03	-2.96	3.17E-03	NA	NA	NA	NA
RAB13	Ras-related protein Rab-13	P51153	RAB13	2.58	3.25E-03	-1.94	0.026	0.04	0.175	-0.16	0.154
MOT1	Monocarboxylate transporter 1	P53985	SLC16A1	2.24	6.75E-03	-1.39	7.07E-03	-0.71	2.77E-03	0.22	0.092
TIDC1	Complex I assembly factor TIMMDC1, mitochondrial	Q9NPL8	TIMMDC1	2.13	3.06E-04	-1.37	4.51E-03	-0.43	8.16E-03	-0.06	0.197
ERBB3	Receptor tyrosine-protein kinase erbB-3	P21860	ERBB3	1.68	0.031	-2.12	5.94E-03	NA	NA	NA	NA
RS23	40S ribosomal protein S23	P62266	RPS23	1.61	0.019	-1.53	0.020	-0.09	0.107	-0.19	0.253
RT12	28S ribosomal protein S12, mitochondrial	O15235	MRPS12	1.56	8.30E-03	-1.53	0.011	NA	NA	NA	NA
TBAL3	Tubulin alpha chain-like 3	A6NHL2	TUBAL3	1.32	0.047	-1.82	0.045	-0.23	0.166	-0.34	0.056

PTL parthenolide




Fig. 3 **A** 23 potential interaction partners of DSC1 modulated by parthenolide. **B** Known interaction partners of DSC1 in the STRING database

Gene Ontology Biological Process Pathway Name	MCF7-DSC1-GFP vs. MCF7-GFP	MCF7-DSC1-GFP + PTL vs. MCF7-DSC1-GFP	Core Enriched Proteins
ACTIN_FILAMENT_BASED_PROCESS	●		DSG2, CTNA1, CELR1, AT1A1, FAT1
REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS	●		DSG2, CELR1, AT1A1
CELL_CELL_ADHESION	●		DSG2, CELR2, CTNA1, CELR1, TFR1, CADH1, FAT1, CTNB1, DNJA3, PCDH1, EPCAM, PCDB3, SPIT2, ERBB2, PCDBD, SCRIB, CADH3, PCDGD
HOMOPHILIC_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES	●	●	DSG2, CELR2, CELR1, CADH1, FAT1, PCDH1, PCDB3, PCDBD, CADH3, PCDGD, PCDGH
CELL_CELL_ADHESION_VIA_PLASMA_MEMBRANE_ADHESION_MOLECULES		●	DSG2, CELR2, CELR1, CADH1, FAT1, PCDH1, PCDB3, PCDBD, CADH3, PCDGD, PCDGH
EMBRYONIC_MORPHOGENESIS		●	<i>TBR1, SP3, SEM4C, RL38, RET, MYADM, CELR1, FREM2</i>




Fig. 4 Gene set enrichment analysis of proteins that are not co-expressed with DSC1 and were identified in pull-down from MCF7-DSC1-GFP vs. MCF7-GFP cells treated and untreated with parthenolide. Proteins in italics were enriched in comparison MCF7-DSC1-GFP + PTL vs. MCF7-DSC1-GFP only. Proteins in bold were enriched in both comparisons. *PTL* parthenolide

copious desmosome structures. All proteins illustrated on the interaction map showed score >0.950 that corresponds with high probability of correctness of these interactions.

In conclusion, pull-down analysis of DSC1 interacting proteins revealed DSC1 to interact not only with cytoskeletal proteins and proteins mediating cell adhesion, but also with proteins regulating cell proliferation, especially tyrosine kinase receptors HER2 and HER3, highlighting possible significant role of DSC1 in breast cancer progression. Moreover, parthenolide was found to modulate DSC1 interacting partners including protein HER3.

Discussion

DSC1 is a transmembrane protein that maintains cell–cell adhesion as a part of desmosomes [23]. Previous studies suggested DSC1 to play a role in progression of various cancer diseases. For instance, DSC1 was found overexpressed in liver metastasis of colorectal tumors [24] and a lack of DSC1 protein in squamous cell carcinoma was associated with increased patient survival [25]. Moreover, DSC1 was found to positively influence β -catenin, c-myc and cyclin D1 signaling pathways leading to cancer progression [26]. Contradictory to these studies, others showed DSC1 protein to be negatively associated with disease progression. Low expression of desmocollins including DSC1 in colorectal carcinoma was related to higher tumor grade [27]. DSC1 was also overexpressed in primary melanoma and downregulated in melanoma metastases [28].

In the context of breast cancer, our previous study [13] revealed increased protein levels of DSC1 in luminal A breast tumors that invaded regional lymph nodes compared to lymph node negative luminal A breast tumors. Moreover, we confirmed DSC1 to increase migration and invasion of MCF7 breast cancer cell line in vitro [13]. Based on this evidence we suggested that DSC1 could be involved in metastatic mechanisms of luminal A breast tumors.

Herein, we firstly investigated DSC1 modulation in breast cancer. In our previous GSEA analysis of 836 primary breast tumor transcription profiles [11], we identified NF- κ B pathway to be associated with positive lymph node status of luminal A patients in general and linked Cdk2 to the high risk of distant metastasis in lymph node negative luminal A patients. Based on these results we proposed a panel of inhibitors of these potential therapeutic targets that previously exhibited ability to suppress luminal A breast cancer in vitro and eventually in vivo. These inhibitors include NF- κ B inhibitor parthenolide and Cdk2 inhibitor norcantharidin with which we tested additional NF- κ B inhibitor niclosamide. Parthenolide inhibits MCF7 mammosphere formation and proliferation of MCF7 cells in vitro [29] and suppresses MCF7 mice xenografts [30]. Norcantharidin, clinically used drug for liver cancer treatment [31] was shown to repress breast cancer cell growth, adhesion, and migration and to induce apoptosis [32, 33]. Moreover, niclosamide, Food and Drug Administration-approved drug was found to induce inhibition of breast cancer cell growth [34, 35]. In the present study we tested these inhibitors to identify a modulator of DSC1 expression in luminal A breast cancer cells. We revealed that parthenolide significantly decreased DSC1 protein levels in MCF7 cells producing DSC1. Mechanism of parthenolide inhibition of desmosomal proteins is however not well understood to date. Nevertheless, previous studies [36–39] identified parthenolide to covalently bind several protein targets, including NF- κ B factors and kinases

associated with cancer development. Based on this evidence we conclude possible indirect inhibition of DSC1 by parthenolide.

AFM uncovered DSC1 over-expression in MCF7 cells to cause statistically significant decrease of cell height. This can be assumed as a pro-metastatic effect since reduced cell height was linked to metastatic phenotype [40]. Moreover, AFM revealed significant decrease of cell stiffness after parthenolide treatment in DSC1 overexpressing cells. AFM studies offered contradictory evidence on association between cell stiffness and metastatic potential. Some studies [41–43] showed cancer cells to be more elastic than normal cell lines and connected decreased cell stiffness to activation of EMT and invasion of cancer cells to distant tissue. Other studies [44–46] evidenced increased rigidity of cytoplasmic membrane to be associated with higher pro-metastatic properties of cancer cells. Our results suggest that both DSC1 and parthenolide treatment influence morphology of MCF7 cell line.

To study molecular mechanisms associated with DSC1 overexpression and its inhibition by parthenolide, we performed analysis of the total proteome and transcriptome using DIA-LC-MS/MS and RNA-Seq, respectively. The most co-expressed genes with DSC1 modulated by parthenolide treatment were IGFBP5 and LACRT. IGFBP5 participates in cell growth, differentiation of human embryonic cells and in homeostasis in adult cells. Moreover, IGFBP5 can regulate IGF-II [47], apoptotic molecules (bax, bcl-2) [48] and p38 MAP kinase and Erk 1/2 signal transduction pathways [49], and thus influences cell proliferation, migration, survival, adhesion, and apoptosis [50–53]. Nevertheless, the reports of the role of IGFBP5 in cellular growth are contradictory, suggesting a complex role of IGFBP5 in cancer cells, as it can either stimulate or inhibit cell proliferation in various cell types [54]. IGFBP5 was revealed to stimulate cell migration in breast cancer [54]. Clinical observations provided supporting evidence that IGFBP5 is associated with metastasis and the aggressive tumor phenotype in breast cancer [55–58]. IGFBP5 was found overexpressed in breast tumors compared to normal breast tissues [59–61]. Hao et al. showed increased expression of IGFBP5 in lymph node metastases of breast carcinoma [57] and Li et al. demonstrated association between increased transcript levels of IGFBP5 and axillary lymph node metastasis and estrogen receptor expression in breast tumors [62]. Increased transcript levels of IGFBP5 also correlated with decreased survival of lymph node negative and estrogen receptor negative patients [62]. Contrary to these findings, IGFBP5 was found to inhibit growth of breast cancer cells in vitro and in vivo [48] and IGFBP5 overexpression was associated with improved breast cancer patient outcome in another study [63]. This inconsistency in suggestions of IGFBP5 role in breast cancer could be due to IGFBP5 protein cellular localization that seems to affect its ability to promote or inhibit breast cancer progression [64]. Tumor tissues mainly contain cytoplasmic IGFBP5, whereas cell lines with exogenously introduced IGFBP5 include mainly nuclear IGFBP5 acting as a growth inhibitor. Change of IGFBP5 localization from nucleus to cytoplasm switched IGFBP5 to a promoter of growth and migration [64]. This is in agreement with clinical observations indicating cytoplasmic IGFBP5 as a marker of poor prognosis [64]. LACRT is a glycoprotein that functions as a mitogen and promotes homeostasis and proliferation in human corneal epithelial cells [65, 66]. Mitogenic function of LACRT via NFAT and mTOR activation was observed in

human embryonic kidney cells and human corneal epithelial cells [67]. LACRT was found expressed in normal breast tissue, breast tumors and breast cancer cell lines [68]. Amplification of LACRT gene was reported to be associated with invasion of breast tumors and was suggested as a marker for circulating breast cancer cells [69] which indicates connection of LACRT to metastatic behavior of breast tumors. These results suggest that DSC1-related molecular mechanisms supporting the lymph node metastasis development of luminal breast tumors could be associated with IGFBP5, known regulator of cell growth, migration, and proliferation, and with proliferation-promoting protein LACRT.

We further showed DSC1 overexpression to be associated with enrichment of MCM pathway that consists of CDK2 and MCM subunits 2–7. CDK2 binds to cyclin partners and promotes cell cycle progression [70, 71], whereas MCM2-7 complex acts as helicase and enables DNA replication during the S phase of the cell cycle [72]. Enrichment of this pathway supports the findings of association between DSC1 and proteins involved in proliferation in MCF7 breast cancer cells with potential to promote breast tumor aggressiveness and metastatic behavior.

Mechanisms of parthenolide-induced DSC1 inhibition include downregulation of IGFBP5 and LACRT together with proliferative proteins of MCM pathway. From these results we suggest that parthenolide treatment could target cellular mechanisms connected to DSC1 in luminal A breast cancer cells.

We have next focused on cellular mechanisms associated with DSC1 via protein–protein interactions. Previously known interaction partners of DSC1 include desmosomal proteins involved in cell adhesion and proteins related to epithelial cell phenotype. In concordance with main role of DSC1 in mediating cell adhesion through desmosome formation and interactions with desmosomal proteins [73, 74], potential DSC1 interacting proteins identified in our pull-down experiment involve mainly cadherins, namely DSG2, CDH1, CDH3 and several protocadherins. Cadherins typically participate in cell–cell adhesion, however cadherins are also known to interact with junctional proteins (such as β -catenin) and with growth factor receptors and thus can affect cell proliferation, motility, and survival [75]. CDH1 is a tumor suppressor that inhibits multiple steps of metastatic cascade [76]. CDH3 is a vital protein in maintenance of correct tissue architecture [77]. In breast cancer, overexpression of CDH3 is connected to more aggressive tumor behavior and poor patient survival [78, 79]. We found DSC1 to interact also with tyrosine kinase receptors HER2 and HER3 and parthenolide to modulate this DSC1-HER3 interaction. HER2 is an oncogene that serves as a very important clinical marker and therapeutic target in breast cancer [80]. HER3 is known to participate in oncogenic signaling through activation of the PI-3 K/Akt pathway and Src kinase, which induces cell proliferation and survival [81–83]. Further, HER3 is important for cell motility and enhances metastatic potential of breast tumor cells [84]. Increased expression of HER3 in multiple cancer diseases including breast cancer results in decreased patient survival [85] and treatment failures in cancer therapy [86–88]. Based on the results of this study supporting previous evidence of DSC1 role in breast cancer metastasis we conclude that DSC1 could participate in breast tumor progression by co-expression with genes involved in cell proliferation in the early stage of the disease, and support the

formation of secondary tumors via physical interactions of DSC1 protein with proteins maintaining cellular adhesion in the later stage of the disease.

Conclusions

We show association of DSC1, protein previously linked with lymph node metastasis of luminal A breast tumors, with increased metastatic potential of luminal A breast cancer cells in vitro. Although DSC1 is primarily involved in cell adhesion, proteomics and transcriptomics analysis reveal DSC1 to increase expression of IGFBP5 and LACRT and to positively regulate pathway of cell proliferation. Moreover, our results indicate potential regulation of DSC1 by NF- κ B inhibitor parthenolide as we identified parthenolide to reduce DSC1 protein levels in MCF7 breast cancer cells as well as expression of IGFBP5, LACRT genes and proliferative pathway. Besides cell adhesion proteins as CDH1, CDH3 and DSG2, DSC1 interacts with tyrosine kinase receptors HER2 and HER3. Our data indicate that DSC1 is connected to cell migration, invasion, and cell cycle regulation in luminal A breast cancer cells, and can be effectively modulated by parthenolide. Based on these results we conclude that DSC1 could be involved in breast tumor proliferation and development in the early stage, and in tumor cell adhesion to metastatic sites in the later stage of the disease supporting generation of secondary tumors.

Abbreviations

ACN	Acetonitrile
AFM	Atomic force microscopy
CDH1	Cadherin 1
CDH3	Cadherin 3
CDK2	Cyclin-dependent kinase 2
CTNA1	Catenin alpha-1
DIA	Data independent acquisition
DMEM	Dulbecco's Modified Eagle's Medium
DMSO	Dimethyl sulfoxide
DSC1	Desmocollin-1
DSG2	Desmoglein 2
ECL	Enhanced chemiluminescence
EVPL	Envoplakin
FA	Formic acid
FASP	Filter-aided sample preparation
FBS	Fetal bovine serum
GFP	Green fluorescent protein
GOBP	Gene ontology biological process
GSEA	Gene set enrichment analysis
HCD	Higher-energy collisional dissociation
HER2	Receptor tyrosine-protein kinase erbB-2
HER3	Receptor tyrosine-protein kinase erbB-3
IGFBP5	Insulin-like growth factor-binding protein 5
LACRT	Extracellular glycoprotein lacritin
LC-MS/MS	Liquid chromatography-tandem mass spectrometry
MCM	Minichromosome maintenance
NF- κ B	Nuclear factor kappa-light-chain-enhancer of activated B cells
PBS	Phosphate buffered saline
PPL	Periplakin
RNA-Seq	RNA sequencing
SBP	Streptavidin-binding peptide

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s11658-023-00481-6>.

Additional file 1: Fig. S1. Western blot analysis of DSC1 modulation using inhibitors niclosamide, norcantharidin and parthenolide. (A) processed images, (B) raw image of immunoblotting with anti-DSC1 antibody, (C) raw image

of immunoblotting with anti-ACTB antibody. Tab. S1 Statistical evaluation of semiquantitative analysis of effect of inhibitors on protein levels of DSC1 longer and shorter isoforms. Fig. S2 (A) Representative chromatograms of iRT peptides measured in the total proteome experiment displayed in Skyline software, (B) iRT calibration chart used in the directDIA analysis in Spectronaut software. Tab. S2 Proteins significantly up-regulated after DSC1 overexpression. Fig. S3 Western blot verification of SBP tag presence in control MCF7-GFP cells and MCF7-DSC1-GFP cells used for pull-down identification of DSC1 protein interaction partners. Antibodies: Anti-SBP-tag (left), Anti-DSC1 (right) and Anti-ACTB (down).

Additional file 2. Total proteome experiment results. A) Mass spectrometry protein group level data from total proteome experiment comparing protein levels in MCF7-DSC1-GFP and control MCF7-GFP cell line. B) Mass spectrometry protein group level data from total proteome experiment comparing protein levels in MCF7-DSC1-GFP cell line treated with parthenolide and MCF7-DSC1-GFP cell line treated with DMSO. C) Mass spectrometry protein group level data from total proteome experiment comparing protein levels in MCF7-GFP cell line treated with parthenolide and MCF7-GFP cell line treated with DMSO. D) Mass spectrometry protein group level data from total proteome experiment comparing protein levels in MCF7-DSC1-GFP cell line treated with parthenolide and MCF7-GFP cell line treated with parthenolide.

Additional file 3. Results of RNA-Seq analysis of total transcriptome. A) RNA-Seq protein-coding transcript level data from transcriptomics experiment comparing transcript profiles in MCF7-DSC1-GFP and control MCF7-GFP cell line. B) RNA-Seq protein-coding transcript level data from transcriptomics experiment comparing transcript profiles in MCF7-DSC1-GFP cell line treated with parthenolide and MCF7-DSC1-GFP cell line treated with DMSO. C) RNA-Seq protein-coding transcript level data from transcriptomics experiment comparing transcript profiles in MCF7-GFP cell line treated with parthenolide and MCF7-GFP cell line treated with DMSO. D) RNA-Seq protein-coding transcript level data from transcriptomics experiment comparing transcript profiles in MCF7-DSC1-GFP cell line treated with parthenolide and MCF7-GFP cell line treated with parthenolide.

Additional file 4. Results of Gene Set Enrichment Analysis (GSEA) of A) total proteome data and B) transcriptomics data including GSEA enriched pathways and core enriched genes.

Additional file 5. Results of the pull-down identification of DSC1 protein interaction partners. A) Mass spectrometry protein group level data from pull-down experiment comparing protein levels in MCF7-DSC1-GFP and control MCF7-GFP cell line pull-downs. B) Mass spectrometry protein group level data from pull-down experiment comparing protein levels in MCF7-DSC1-GFP cell line treated with parthenolide and MCF7-DSC1-GFP treated with DMSO cell line pull-downs. C) Proteins significantly upregulated (q -value < 0.05 and $\text{Log}_2 \text{FC} > 1$) in pull-down without parthenolide (PTL) treatment (comparison MCF7-DSC1-GFP vs. MCF7-GFP) and not statistically significantly upregulated in total proteome analysis (either " q -value > 0.05 when $\text{Log}_2 \text{FC} > 0$ " or " $\text{Log}_2 \text{FC} < 0$ " or not identified) in total proteome comparison MCF7-DSC1-GFP vs. MCF7-GFP.

Additional file 6. Results of Gene Set Enrichment Analysis (GSEA) of pull-down data including GSEA enriched pathways and core enriched genes.

Acknowledgements

We would like to thank Roman Hrstka (Masaryk Memorial Cancer Institute) for preparing RNA-Seq libraries, and to Saltuk Mustafa Eyrilmez (Masaryk University) for consultation regarding mechanisms of DSC1-parthenolide interaction for the review. We would also like to thank those who contributed with the data obtained as a paid service: Jan Pribyl (Masaryk University, AFM), Vojtech Bystry and Vaclav Hejret (Masaryk University, RNA-Seq data analysis).

Author contributions

PL processed proteomics and pull-down samples, visualized the data, and drafted the manuscript. PS and KJ grew the cells, PS performed western blot analyses and inhibitor selection and KJ performed pull-down experiment. DP measured the proteomics samples using LC-MS/MS. PB processed samples for transcriptomics analysis. PL, PB, PS, KJ and LJ processed and interpreted the results. PB and PM designed the stably transduced cell lines. PB designed and supervised the project, secured the funding, and finalized the manuscript. All authors reviewed the manuscript.

Funding

This work was supported by Ministry of Health of the Czech Republic, grant nr. NU22-08-00230, all rights reserved. CIISB, Instruct-CZ Centre of Instruct-ERIC EU consortium, funded by MEYS CR infrastructure project LM2023042 and European Regional Development Fund-Project „UP CIISB“ (No. CZ.02.1.01/0.0/0.0/18_046/0015974), is gratefully acknowledged for the financial support of the measurements at the CEITEC Proteomics Core Facility (by DP) and for the AFM measurements at Nanobiotechnology core facility. Bioinformatics Core Facility of CEITEC Masaryk University supported by the NCMG research infrastructure (LM2018132 funded by MEYS CR) is acknowledged for RNA-Seq data analysis. Supported by the project National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102)—Funded by the European Union—Next Generation EU.

Availability of data and materials

The raw mass spectrometry proteomics data and output files for the total proteome and pull-down analyses have been deposited in the ProteomeXchange Consortium via the Proteomics Identifications (PRIDE) partner repository (<http://www.ebi.ac.uk/pride/archive/>) with the dataset identifier PXD041029. The raw and processed RNA-Seq data have been deposited in NCBI's Gene Expression Omnibus [89] and are accessible through GEO Series accession number GSE228017 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228017>).

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 19 April 2023 Accepted: 27 July 2023

Published online: 24 August 2023

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209–49.
2. Dai X, Xiang L, Li T, Bai Z. Cancer hallmarks, biomarkers and breast cancer molecular subtypes. *J Cancer*. 2016;7(10):1281–94.
3. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature*. 2000;406(6797):747–52.
4. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA*. 2001;98(19):10869–74.
5. Harbeck N, Gnant M. Breast cancer. *Lancet*. 2017;389(10074):1134–50.
6. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. *Breast Cancer Res*. 2011;13(6):221.
7. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. *Breast*. 2015;24(Suppl 2):S26–35.
8. Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, et al. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. *Cancer Res*. 2013;73(12):3783–95.
9. KaramiFath M, Azargoonjahromi A, Kiani A, Jalalifar F, Osati P, Akbari Oryani M, et al. The role of epigenetic modifications in drug resistance and treatment of breast cancer. *Cell Mol Biol Lett*. 2022;27(1):52.
10. Buonomo OC, Caredda E, Portarena I, Vanni G, Orlandi A, Bagni C, et al. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. *PLoS ONE*. 2017;12(9): e0184680.
11. Lapcik P, Pospisilova A, Janacova L, Grell P, Fabian P, Bouchal P. How different are the molecular mechanisms of nodal and distant metastasis in luminal A breast cancer? *Cancers (Basel)*. 2020;12(9):E2638.
12. Tang Y, Wang Y, Kiani MF, Wang B. Classification, treatment strategy, and associated drug resistance in breast cancer. *Clin Breast Cancer*. 2016;16(5):335–43.
13. Faktor J, Knopfova L, Lapcik P, Janacova L, Paralova V, Bouchalova P, et al. Proteomics identification and validation of desmocollin-1 and catechol-O-methyltransferase as proteins associated with breast cancer cell migration and metastasis. *Proteomics*. 2019;19(21–22): e1900073.
14. Kottke MD, Delva E, Kowalczyk AP. The desmosome: cell science lessons from human diseases. *J Cell Sci*. 2006;119(Pt 5):797–806.
15. O'Shea C, Fitzpatrick JE, Koch PJ. Desmosomal defects in acantholytic squamous cell carcinomas. *J Cutan Pathol*. 2014;41(11):873–9.
16. Khan K, Hardy R, Haq A, Ogunbiyi O, Morton D, Chidgey M. Desmocollin switching in colorectal cancer. *Br J Cancer*. 2006;95(10):1367–70.
17. Faktor J, Sucha R, Paralova V, Liu Y, Bouchal P. Comparison of targeted proteomics approaches for detecting and quantifying proteins derived from human cancer tissues. *Proteomics*. 2017. <https://doi.org/10.1002/pmic.201600323>.
18. Maryáš J, Faktor J, Čápková L, Müller P, Skládál P, Bouchal P. Pull-down assay on streptavidin beads and surface plasmon resonance chips for SWATH-MS-based interactomics. *Cancer Genomics Proteomics*. 2018;15(5):395–404.
19. Wiśniewski JR, Ostasiewicz P, Mann M. High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. *J Proteome Res*. 2011;10(7):3040–9.
20. Bouchal P, Roumeliotis T, Hrstka R, Nenutil R, Vojtesek B, Garbis SD. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. *J Proteome Res*. 2009;8(1):362–73.
21. Stejskal K, Potěšil D, Zdráhal Z. Suppression of peptide sample losses in autosampler vials. *J Proteome Res*. 2013;12(6):3057–62.
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*. 2005;102(43):15545–50.
23. Getsios S, Amargo EV, Dusek RL, Ishii K, Sheu L, Godsel LM, et al. Coordinated expression of desmoglein 1 and desmocollin 1 regulates intercellular adhesion. *Differentiation*. 2004;72(8):419–33.

24. Schüle S, Neuhäuser C, Rauchfuß F, Knösel T, Settmacher U, Altendorf-Hofmann A. The influence of desmocollin 1–3 expression on prognosis after curative resection of colorectal liver metastases. *Int J Colorectal Dis.* 2014;29(1):9–14.
25. Myklebust MP, Fluge Ø, Immervoll H, Skarstein A, Balteskard L, Bruland O, et al. Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients. *Br J Cancer.* 2012;106(4):756–62.
26. Wang Y, Chen C, Wang X, Jin F, Liu Y, Liu H, et al. Lower DSC1 expression is related to the poor differentiation and prognosis of head and neck squamous cell carcinoma (HNSCC). *J Cancer Res Clin Oncol.* 2016;142(12):2461–8.
27. Knösel T, Chen Y, Hotovy S, Settmacher U, Altendorf-Hofmann A, Petersen I. Loss of desmocollin 1–3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma. *Int J Colorectal Dis.* 2012;27(11):1391–9.
28. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. *Clin Cancer Res.* 2007;13(3):806–15.
29. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. *Breast Cancer Res Treat.* 2008;111(3):419–27.
30. Liu Y, Lu WL, Guo J, Du J, Li T, Wu JW, et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. *J Control Release.* 2008;129(1):18–25.
31. Zhang X, Zhang B, Zhang P, Lian L, Li L, Qiu Z, et al. Norcantharidin regulates ERa signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells. *PLoS ONE.* 2019;14(5): e0217181.
32. Shou LM, Zhang QY, Li W, Xie X, Chen K, Lian L, et al. Cantharidin and norcantharidin inhibit the ability of MCF-7 cells to adhere to platelets via protein kinase C pathway-dependent downregulation of $\alpha 2$ integrin. *Oncol Rep.* 2013;30(3):1059–66.
33. Yang PY, Chen MF, Kao YH, Hu DN, Chang FR, Wu YC. Norcantharidin induces apoptosis of breast cancer cells: involvement of activities of mitogen activated protein kinases and signal transducers and activators of transcription. *Toxicol In Vitro.* 2011;25(3):699–707.
34. Liu FL, Chen CL, Lee CC, Wu CC, Hsu TH, Tsai CY, et al. The simultaneous inhibitory effect of niclosamide on RANKL-induced osteoclast formation and osteoblast differentiation. *Int J Med Sci.* 2017;14(9):840–52.
35. Ye T, Xiong Y, Yan Y, Xia Y, Song X, Liu L, et al. The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. *PLoS ONE.* 2014;9(1): e85887.
36. Dawood M, Ooko E, Efferth T. Collateral sensitivity of parthenolide via NF-kB and HIF- α inhibition and epigenetic changes in drug-resistant cancer cell lines. *Front Pharmacol.* 2019;10:542.
37. Berdan CA, Ho R, Lehtola HS, To M, Hu X, Huffman TR, et al. Parthenolide covalently targets and inhibits focal adhesion kinase in breast cancer cells. *Cell Chem Biol.* 2019;26(7):1027–1035.e22.
38. Kwok BH, Koh B, Ndubuisi MI, Eloffson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits I κ B kinase. *Chem Biol.* 2001;8(8):759–66.
39. Li X, Kong L, Yang Q, Duan A, Ju X, Cai B, et al. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth. *J Biol Chem.* 2020;295(11):3576–89.
40. Raudenska M, Kratochvilova M, Vicar T, Gumulec J, Balvan J, Polanska H, et al. Cisplatin enhances cell stiffness and decreases invasiveness rate in prostate cancer cells by actin accumulation. *Sci Rep.* 2019;9(1):1660.
41. Li QS, Lee GYH, Ong CN, Lim CT. AFM indentation study of breast cancer cells. *Biochem Biophys Res Commun.* 2008;374(4):609–13.
42. Ansardamavandi A, Tafazzoli-Shadpour M, Omidvar R, Jahanzad I. Quantification of effects of cancer on elastic properties of breast tissue by atomic force microscopy. *J Mech Behav Biomed Mater.* 2016;60:234–42.
43. Xu W, Mezenzev R, Kim B, Wang L, McDonald J, Sulchek T. Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. *PLoS ONE.* 2012;7(10): e46609.
44. Bastatas L, Martinez-Marin D, Matthews J, Hashem J, Lee YJ, Sennoune S, et al. AFM nano-mechanics and calcium dynamics of prostate cancer cells with distinct metastatic potential. *Biochim Biophys Acta.* 2012;1820(7):1111–20.
45. Zhang G, Long M, Wu ZZ, Yu WQ. Mechanical properties of hepatocellular carcinoma cells. *World J Gastroenterol.* 2002;8(2):243–6.
46. Faria EC, Ma N, Gazi E, Gardner P, Brown M, Clarke NW, et al. Measurement of elastic properties of prostate cancer cells using AFM. *Analyst.* 2008;133(11):1498–500.
47. Ren H, Yin P, Duan C. IGFBP-5 regulates muscle cell differentiation by binding to IGF-II and switching on the IGF-II auto-regulation loop. *J Cell Biol.* 2008;182(5):979–91.
48. Butt AJ, Dickson KA, McDougall F, Baxter RC. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. *J Biol Chem.* 2003;278(32):29676–85.
49. Kuemmerle JF, Zhou H. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates growth and IGF-I secretion in human intestinal smooth muscle by Ras-dependent activation of p38 MAP kinase and Erk1/2 pathways. *J Biol Chem.* 2002;277(23):20563–71.
50. Sun M, Long J, Yi Y, Xia W. Importin α -importin β complex mediated nuclear translocation of insulin-like growth factor binding protein-5. *Endocr J.* 2017;64(10):963–75.
51. Flint DJ, Tonner E, Allan GJ. Insulin-like growth factor binding proteins: IGF-dependent and -independent effects in the mammary gland. *J Mammary Gland Biol Neoplasia.* 2000;5(1):65–73.
52. McCaig C, Perks CM, Holly JMP. Signalling pathways involved in the direct effects of IGFBP-5 on breast epithelial cell attachment and survival. *J Cell Biochem.* 2002;84(4):784–94.
53. McCaig C, Perks CM, Holly JMP. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. *J Cell Sci.* 2002;115(Pt 22):4293–303.

54. Güllü G, Karabulut S, Akkiprik M. Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. *Chin J Cancer*. 2012;31(6):266–80.
55. Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, et al. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. *Int J Oncol*. 2004;25(4):797–819.
56. Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, et al. Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. *Jpn J Clin Oncol*. 2007;37(8):575–82.
57. Hao X, Sun B, Hu L, Lähdesmäki H, Dunmire V, Feng Y, et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. *Cancer*. 2004;100(6):1110–22.
58. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, et al. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. *Breast J*. 2008;14(3):261–7.
59. Pekonen F, Nyman T, Ilvesmäki V, Partanen S. Insulin-like growth factor binding proteins in human breast cancer tissue. *Cancer Res*. 1992;52(19):5204–7.
60. McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. *Cancer Lett*. 1994;77(1):25–32.
61. Akkiprik M, Feng Y, Wang H, Chen K, Hu L, Sahin A, et al. Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. *Breast Cancer Res*. 2008;10(4):212.
62. Li X, Cao X, Li X, Zhang W, Feng Y. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. *Cancer Sci*. 2007;98(10):1592–6.
63. Ahn BY, Elwi AN, Lee B, Trinh DLN, Klimowicz AC, Yau A, et al. Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. *Cancer Res*. 2010;70(8):3013–9.
64. Akkiprik M, Hu L, Sahin A, Hao X, Zhang W. The subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer. *BMC Cancer*. 2009;9:103.
65. Wang N, Zimmerman K, Raab RW, McKown RL, Hutnik CML, Talla V, et al. Lacritin rescues stressed epithelia via rapid forkhead box O3 (FOXO3)-associated autophagy that restores metabolism. *J Biol Chem*. 2013;288(25):18146–61.
66. Feng MM, Baryla J, Liu H, Laurie GW, McKown RL, Ashki N, et al. Cytoprotective effect of lacritin on human corneal epithelial cells exposed to benzalkonium chloride in vitro. *Curr Eye Res*. 2014;39(6):604–10.
67. Wang N, Xie J, Walton SC, McKown RL, Raab RW, et al. Restricted epithelial proliferation by lacritin via PKC α -dependent NFAT and mTOR pathways. *J Cell Biol*. 2006;174(5):689–700.
68. Weigelt B, Bosma AJ, van't Veer LJ. Expression of a novel lacrimal gland gene lacritin in human breast tissues. *J Cancer Res Clin Oncol*. 2003;129(12):735–6.
69. Ma P, Beck SL, Raab RW, McKown RL, Coffman GL, Utani A, et al. Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin. *J Cell Biol*. 2006;174(7):1097–106.
70. Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. *Cell Death Differ*. 2002;9(12):1287–93.
71. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. *Oncogene*. 2005;24(17):2776–86.
72. Guo Y, Fan Y, Zhang J, Chang L, Lin JD, Chen YE. Peroxisome proliferator-activated receptor γ coactivator 1 β (PGC-1 β) protein attenuates vascular lesion formation by inhibition of chromatin loading of minichromosome maintenance complex in smooth muscle cells. *J Biol Chem*. 2013;288(7):4625–36.
73. Kowalczyk AP, Green KJ. Structure, function, and regulation of desmosomes. *Prog Mol Biol Transl Sci*. 2013;116:95–118.
74. Garrod D, Chidgey M. Desmosome structure, composition and function. *Biochim Biophys Acta*. 2008;1778(3):572–87.
75. Breier G, Grosser M, Rezaei M. Endothelial cadherins in cancer. *Cell Tissue Res*. 2014;355(3):523–7.
76. Na TY, Schecterson L, Mendonsa AM, Gumbiner BM. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. *Proc Natl Acad Sci U S A*. 2020;117(11):5931–7.
77. Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC. P-cadherin expression in breast cancer: a review. *Breast Cancer Res*. 2007;9(5):214.
78. Albergaria A, Ribeiro AS, Vieira AF, Sousa B, Nobre AR, Seruca R, et al. P-cadherin role in normal breast development and cancer. *Int J Dev Biol*. 2011;55(7–9):811–22.
79. Ribeiro AS, Sousa B, Carreto L, Mendes N, Nobre AR, Ricardo S, et al. P-cadherin functional role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model. *J Pathol*. 2013;229(5):705–18.
80. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet*. 2017;389(10075):1195–205.
81. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. *Proc Natl Acad Sci U S A*. 2003;100(15):8933–8.
82. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. *Cancer Res*. 2008;68(14):5878–87.
83. Lee Y, Ma J, Lyu H, Huang J, Kim A, Liu B. Role of erbB3 receptors in cancer therapeutic resistance. *Acta Biochim Biophys Sin (Shanghai)*. 2014;46(3):190–8.
84. Xue C, Liang F, Mahmood R, Vuolo M, Wyckoff J, Qian H, et al. ErbB3-dependent motility and intravasation in breast cancer metastasis. *Cancer Res*. 2006;66(3):1418–26.
85. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. *J Natl Cancer Inst*. 2013;105(4):266–73.
86. Lyu H, Han A, Polsdofer E, Liu S, Liu B. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. *Acta Pharm Sin B*. 2018;8(4):503–10.
87. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. *Semin Cell Dev Biol*. 2010;21(9):944–50.

88. Ma J, Lyu H, Huang J, Liu B. Targeting of erbB3 receptor to overcome resistance in cancer treatment. *Mol Cancer*. 2014;13:105.
89. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. *Nucleic Acids Res*. 2013;41(Database issue):D991-995.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

